Research Article

Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients

Table 1

Patient characteristics: MM patients.

Poor mobilizers ( )Good mobilizers ( )

Age, median (range), years61 (48–67)65.5 (30–73)

Sex
 Male
 Female
8
0
5
5

Disease stage
 II
 III
2
6
4
6

Disease status
 CR/VGPR
 PR
 DP
2
6
0*
3
7
0

B2M
Chromosome 13q/13 del
2.74 (1.68–5.84)
2
3.09 (1.3–5.18)
4

Median no. of prior treatment regimens (range)1 (1–3)1 (1–3)

Prior lenalidomide (≥4 cycles)20

Prior RT26

Median time from diagnosis (range), days206 (129–462)204 (109–377)

Patients who had two transplants:
 As salvage
 As tandem
1
1
1

Posttransplant maintenance**56

*One patient was in PR at first mobilization; however, he developed disease progression by the time he went through the plerixafor mobilization. The patient did not go through ASCT, and he was excluded from survival analysis.
**At 3 months of evaluation posttransplant, patients were offered maintenance therapy with thalidomide.
Note. The results show number of patients in each category unless indicated otherwise.